Regional Underreporting of Associated Congenital Anomalies in Cleft Patients in the Netherlands

2006 ◽  
Vol 43 (6) ◽  
pp. 710-714 ◽  
Author(s):  
F. J. C. van der Veen ◽  
J. M. van Hagen ◽  
J. Berkhof ◽  
J. P. W. Don Griot
Keyword(s):  
The Netherlands ◽  
Birth Cohort ◽  
Congenital Anomalies ◽  
Cleft Lip ◽  
First Year ◽  
Medical File ◽  
Early Registration ◽  
First Year Of Life

Objective: The Dutch Cleft Palate Association (DCPA) registers all patients with cleft lip or palate and associated congenital anomalies in the Netherlands. The aim of this study was to assess if early registration of cleft patients leads to underreporting of associated congenital anomalies and, if so, whether reregistration is necessary. Methods: The DCPA registration of the birth cohort 1997 to 2001 was compared with the medical files of these cleft patients for prevalence, type, and moment of registration of associated congenital anomalies. To assess possible long-term underregistration, a second birth cohort of 1990 to 1991 was analyzed. Results: The percentage of cleft patients with associated congenital anomalies was 26% in the DCPA database and 33% in the retrospective medical file review. A syndrome, sequence, or association was recognized in 8% of the cleft patients by the DCPA compared with 13% in our medical file review. Of all associated congenital anomalies diagnosed during a follow-up of 12 years, 53% were diagnosed in the first year of life. The cumulative percentage was 59% after 2 years, 62% after 3 years, 80% after 6 years, and 97% after 10 years. Conclusion: Early registration of cleft patients leads to underreporting of other associated anomalies. For a complete registration of associated congenital anomalies in cleft patients, reregistration at a later age is necessary.

Muenke syndrome: long-term outcome of a syndrome-specific treatment protocol

2019 ◽  
Vol 24 (4) ◽  
pp. 415-422 ◽  
Author(s):  
Bianca K. den Ottelander ◽  
Robbin de Goederen ◽  
Marie-Lise C. van Veelen ◽  
Stephanie D. C. van de Beeten ◽  
Maarten H. Lequin ◽  
...  
Keyword(s):  
Treatment Protocol ◽  
First Year ◽  
Ventricular Size ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Skull Growth ◽  
Muenke Syndrome ◽  
First Year Of Life

OBJECTIVEThe authors evaluated the long-term outcome of their treatment protocol for Muenke syndrome, which includes a single craniofacial procedure.METHODSThis was a prospective observational cohort study of Muenke syndrome patients who underwent surgery for craniosynostosis within the first year of life. Symptoms and determinants of intracranial hypertension were evaluated by longitudinal monitoring of the presence of papilledema (fundoscopy), obstructive sleep apnea (OSA; with polysomnography), cerebellar tonsillar herniation (MRI studies), ventricular size (MRI and CT studies), and skull growth (occipital frontal head circumference [OFC]). Other evaluated factors included hearing, speech, and ophthalmological outcomes.RESULTSThe study included 38 patients; 36 patients underwent fronto-supraorbital advancement. The median age at last follow-up was 13.2 years (range 1.3–24.4 years). Three patients had papilledema, which was related to ophthalmological disorders in 2 patients. Three patients had mild OSA. Three patients had a Chiari I malformation, and tonsillar descent < 5 mm was present in 6 patients. Tonsillar position was unrelated to papilledema, ventricular size, or restricted skull growth. Ten patients had ventriculomegaly, and the OFC growth curve deflected in 3 patients. Twenty-two patients had hearing loss. Refraction anomalies were diagnosed in 14/15 patients measured at ≥ 8 years of age.CONCLUSIONSPatients with Muenke syndrome treated with a single fronto-supraorbital advancement in their first year of life rarely develop signs of intracranial hypertension, in accordance with the very low prevalence of its causative factors (OSA, hydrocephalus, and restricted skull growth). This illustrates that there is no need for a routine second craniofacial procedure. Patient follow-up should focus on visual assessment and speech and hearing outcomes.

scholarly journals Closer to the Gold Standard: An Appraisal of Formulae Available in Italy for Use in Formula-fed Infants

2005 ◽  
Vol 33 (6) ◽  
pp. 595-611 ◽  
Author(s):  
E Riva ◽  
E Verduci ◽  
C Agostoni ◽  
M Giovannini
Keyword(s):  
Later Life ◽  
Amino Acid Profile ◽  
First Year ◽  
Breastfed Infants ◽  
Infant Formulae ◽  
Long Term Follow Up ◽  
First Year Of Life

Infant formulae are the only alternatives to breast milk for infants who are unable to continue breastfeeding through the first year of life. They aim to provide formula-fed infants with the same structural and functional benefits observed in breastfed infants. To achieve this, bioactive nutrients have been added to infant formulae in recent years: long-chain polyunsaturated fatty acids for neurodevelopment; probiotics and prebiotics for local gastrointestinal defence; and nucleotides for promoting the immune response. Changes in protein quantity and quality allow infant formulae to achieve a balance between providing the correct plasma amino acid profile and reducing the protein intake, which could prevent obesity in later life. Hydrolysed proteins may help prevent atopic disorders. Many short-term trials have been published but long-term follow-up data are needed in infants who have been fed the newer infant formulae, to fully understand the role of bioactive nutrients.

scholarly journals Systematic review of the healthcare cost of bronchopulmonary dysplasia

BMJ Open ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. e045729
Author(s):  
Jhangir Humayun ◽  
Chatarina Löfqvist ◽  
David Ley ◽  
Ann Hellström ◽  
Hanna Gyllensten
Keyword(s):  
Systematic Review ◽  
Quality Assessment ◽  
Preterm Infants ◽  
Bronchopulmonary Dysplasia ◽  
Gestational Age ◽  
First Year ◽  
Long Term Follow Up ◽  
First Year Of Life

ObjectivesTo determine the costs directly or indirectly related to bronchopulmonary dysplasia (BPD) in preterm infants. The secondary objective was to stratify the costs based on gestational age and/or birth weight.DesignSystematic literature review.SettingPubMed and Scopus were searched on 3 February 2020. Studies were selected based on eligibility criteria by two independent reviewers. Included studies were further searched to identify eligible references and citations.Two independent reviewers extracted data with a prespecified data extraction sheet, including items from a published checklist for quality assessment. The costs in the included studies are reported descriptively.Primary outcome measureCosts of BPD.ResultsThe 13 included studies reported the total costs or marginal costs of BPD. Most studies reported costs during birth hospitalisation (cost range: Int$21 392–Int$1 094 509 per child, equivalent to €19 103–€977 397, in 2019) and/or during the first year of life. One study reported costs during the first 2 years; two other studies reported costs later, during the preschool period and one study included a long-term follow-up. The highest mean costs were associated with infants born at extremely low gestational ages. The quality assessment indicated a low risk of bias in the reported findings of included studies.ConclusionsThis study was the first systematic review of costs associated with BPD. We confirmed previous reports of high costs and described the long-term follow-up necessary for preterm infants with BPD, particularly infants of very low gestational age. Moreover, we identified a need for studies that estimate costs outside hospitals and after the first year of life.PROSPERO registration numberCRD42020173234.

Adult outcome after neurosurgical treatment of brain tumours in the first year of life: long-term follow-up of a single consecutive institutional series of 34 patients

2019 ◽  
Vol 161 (9) ◽  
pp. 1793-1798
Author(s):  
Tryggve Lundar ◽  
Bernt Johan Due-Tønnessen ◽  
Radek Frič ◽  
Petter Brandal ◽  
Einar Stensvold ◽  
...  
Keyword(s):  
Brain Tumours ◽  
First Year ◽  
Adult Outcome ◽  
Long Term Follow Up ◽  
Neurosurgical Treatment ◽  
First Year Of Life

scholarly journals Feeding Calves with Pasteurized Colostrum and Milk Has a Positive Long-Term Effect on Their Productive Performance

Animals ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. 1494
Author(s):  
Ramon Armengol ◽  
Lorenzo Fraile
Keyword(s):  
Respiratory Disease ◽  
Bovine Respiratory Disease ◽  
First Year ◽  
Long Term Effect ◽  
Productive Body ◽  
First Year Of Life ◽  
On Farm ◽  
Health Parameters

Female calves, checked for serum total protein ≥ 5.8 g/dL before 5 days of life, entered the study at 22 days of age after having received pasteurized colostrum and milk (P group, n = 127), or non-pasteurized colostrum and milk (NP group, n = 134). During the heifer-rearing period, productive (body weight; BW) and health parameters (bovine respiratory disease (BRD) and diarrhea) were recorded. Productive (305-d milk yield), reproductive (AI per pregnancy and calving interval), and health parameters (milk somatic cell count; SCC/mL), as well as age at culling, were recorded in a follow-up study. Feeding on-farm pasteurized colostrum and milk during the first 21 days of life reduced morbidity of bovine respiratory disease during the first year of life and diarrhea during the first 180 days of life. Moreover, it increased BW at calving during the first three lactations. It also significantly increases milk production during the first lactation. However, there were no differences in relation to reproductive performance and health of cows in the NP or P group. These results highlight that feeding calves with pasteurized colostrum and milk could improve health and production parameters throughout the heifer-rearing process and during their first lactation.

scholarly journals Bilateral asymptomatic incidental vulvar/labial hemangioma: Kissing Hemangiomas

2011 ◽  
Vol 25 (1) ◽  
pp. 10
Author(s):  
Pankaj P. Dangle ◽  
Lopa K. Pandya IV ◽  
Casimir F. Firlit
Keyword(s):  
Plastic Surgery ◽  
Rare Case ◽  
Watchful Waiting ◽  
Treatment Approach ◽  
First Year ◽  
Labia Majora ◽  
Long Term Follow Up ◽  
First Year Of Life

We present a rare case of genital hemangiomas. Generally, hemangiomas are present at birth or in the first year of life and completely resolve by age 10. Most are asymptomatic. We present an 11 year old girl who presented with incidentally diagnosed asymptomatic bilateral hemangiomas on her labia majora. The treatment for genital hemangiomas is not well defined in the literature. We elected to choose watchful waiting as our treatment approach at this time. Long term follow-up is necessary with intention to intervene with multispeciality approach involving gynaecology and plastic surgery to avoid any disfigurement of the local anatomy.

scholarly journals Birth weight, growth, nutritional status and mortality of infants from Lambaréné and Fougamou in Gabon in their first year of life

PLoS ONE ◽  
2021 ◽  
Vol 16 (2) ◽  
pp. e0246694
Author(s):  
Rella Zoleko-Manego ◽  
Johannes Mischlinger ◽  
Jean Claude Dejon-Agobé ◽  
Arti Basra ◽  
J. Rodolphe Mackanga ◽  
...  
Keyword(s):  
Birth Weight ◽  
Low Birth Weight ◽  
Nutritional Status ◽  
Birth Cohort ◽  
Sub Saharan Africa ◽  
First Year ◽  
First Year Of Life ◽  
Nutritional Deficits ◽  
Prospective Longitudinal

Background Malnutrition and low birth weight (LBW) are two common causes of morbidity and mortality among children in sub-Saharan Africa. Both malnutrition and LBW affect early childhood development with long term consequences that may vary in their degree depending on the geographical setting. This study evaluates growth, nutritional status and mortality of infants from Lambaréné and Fougamou in Gabon from a birth cohort of a malaria in pregnancy clinical trial (NCT00811421). Method A prospective longitudinal birth cohort conducted between 2009 and 2012, included infants that were followed up from birth until their first-year anniversary. The exposure of interest was low birth weight and the outcomes explored were growth represented by weight gain, the nutritional status including stunting, wasting and underweight, and the mortality. Scheduled follow-up visits were at one, nine and 12 months of age. Logistic regression was used to assess the association between low birth weight and growth and nutritional outcomes, and cox regression was used for mortality. Result A total of 907 live-born infants were included in the analysis. The prevalence of LBW was 13% (115). At one month of life, out of 743 infants 10% and 4% presented with stunting and underweight, respectively, while these proportions increased at 12 months of life to 17% and 21%, respectively, out of 530 infants. The proportion of infants with wasting remained constant at 7% throughout the follow-up period. Stunting and underweight were associated with LBW, adjusted odds ratio (aOR): 2.6, 95% confidence interval (95%CI): 1.4–4.9 and aOR: 4.5, 95%CI: 2.5–8.1, respectively. Preterm birth was associated with stunting, aOR: 2.7, 95%CI: 1.2–6.3 and underweight, aOR: 5.4, 95%CI: 1.7–16.1 at one month of life. Infants with LBW were at higher hazard of death during the first year of life, adjusted hazard ratio 4.6, 95%CI: 1.2–17.0. Conclusion Low birthweight infants in Gabon are at higher risks of growth and nutritional deficits and mortality during the first year of life. Tailored interventions aiming at preventing adverse pregnancy outcomes including LBW, early detection and appropriate management of growth, and nutritional deficits in infants are necessary in Gabon.

scholarly journals Long-Term Follow-Up in a Girl with Cystic Fibrosis and Diabetes Since the First Year of Life

2017 ◽  
Vol 8 (5) ◽  
pp. 1187-1190 ◽  
Author(s):  
Valentina Fattorusso ◽  
Alida Casale ◽  
Valeria Raia ◽  
Enza Mozzillo ◽  
Adriana Franzese
Keyword(s):  
Cystic Fibrosis ◽  
First Year ◽  
Long Term Follow Up ◽  
First Year Of Life

Diagnosis, clinical features, management, and post-natal follow-up of fetal tachycardias

2009 ◽  
Vol 19 (5) ◽  
pp. 486-493 ◽  
Author(s):  
Rajka Lulić Jurjević ◽  
Tomaž Podnar ◽  
Samo Vesel
Keyword(s):  
Clinical Features ◽  
Antiarrhythmic Drugs ◽  
Significant Proportion ◽  
First Year ◽  
Fetal Hydrops ◽  
Tertiary Institution ◽  
Long Term Prognosis ◽  
First Year Of Life

AbstractObjectiveTo evaluate the diagnosis, clinical features, management and post-natal follow-up in consecutive fetuses identified with tachycardia.MethodsWe reviewed consecutive fetuses with tachycardia identified in a single tertiary institution between January, 2001, and December, 2008. We considered several options for management, including no treatment but close surveillance, trans-placental antiarrhythmic therapy in fetuses presenting prior to 36 weeks of gestation, and delivery and treatment as a neonate for fetuses presenting after 36 weeks of gestation. Data was gathered by a review of prenatal and postnatal documentation.ResultsAmong 29 fetuses with tachycardia, 21 had supraventricular tachycardia with 1 to 1 conduction, 4 had atrial flutter, 3 had atrial tachycardia, while the remaining fetus had ventricular tachycardia. Of the group, 8 fetuses (27.6%) were hydropic. Transplacental administration of antiarrhythmic drugs was used in just over half the fetuses, delivery and treatment as a neonate in one-quarter, and no intervention but close surveillance in one-sixth of the case. Twenty-six of 29 fetuses (89.7%) were born alive. Only patients with fetal hydrops suffered mortality, with 37.5% of this group dying, this being statistically significant, with the value of p equal to 0.03, when compared to non-hydropic fetuses. Only 3 patients (11.5%) were receiving antiarrhythmic prophylaxis beyond the first year of life.ConclusionA significant proportion of fetal tachycardias recognized before 36 weeks of gestation can be treated successfully by transplacental administration of antiarrhythmic drugs. Fetuses presenting after 36 weeks of gestation can be effectively managed postnatally. The long-term prognosis for fetuses diagnosed with tachycardia is excellent, with the abnormal rhythm resolving spontaneously during the first year of life in most of them.

Sign in / Sign up

Export Citation Format

Share Document